๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Pancreatic Cancer Resectable
Clinical trial register · China

Pancreatic Cancer Resectable Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 4 Hangzhou 3 Xi'an 1 Changsha 1 Xiโ€™an 1
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai4 Hangzhou3 Xi'an1 Changsha1 Xiโ€™an1
All 8 locations
Target enrolment
to

Pancreatic Cancer Resectable trials in China

11 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer
NCT07529626Pancreatic Tumor, Benign, Pancreatic Cancer, Adult, Pancreatic Cancer Resectable
Shanghai Zhongshan Hospital
Observational
320
Changsha, Shanghai, Xiโ€™an
2026-05-11
Not yet open
Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
NCT07469956Pancreatic Cancer Resectable
Sun Yat-sen University
Phase 2
30
Guangzhou
2026-03-31
Active, closed
Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Cancer
NCT07326150Pancreatic Cancer Resectable, Pancreatic Cancer Non-resectable
Zhejiang Cancer Hospital
Observational
70
Zhejiang
2025-12-08
Not yet open
Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer
NCT06941987Minimal Residual Disease, Pancreatic Cancer Resectable
Shanghai Zhongshan Hospital
Observational
66
Shanghai
2025-04-20
Not yet open
Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.
NCT06888674Pancreatic Cancer Resectable
Zhejiang University
Phase 1/2
60
Hangzhou
2025-04-01
Active, closed
Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID)
NCT07157605Pancreatic Cancer Resectable, Pancreatectomy
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Observational
94
Nanjing
2024-11-28
Recruiting
Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer
NCT06722911Pancreatic Cancer Resectable
Zhejiang Provincial People's Hospital
Phase 2
57
Hangzhou
2024-11-15
Not yet open
Early Diagnosis of Pancreatic Cancer Via Deciphering Multi-modal Immunological Signatures
NCT06495749Pancreatic Cancer Resectable
Zhejiang University
Observational
3,000
Hangzhou
2024-08-01
Recruiting
Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer
NCT06496373Pancreatic Cancer Resectable, Chemotherapy-intolerant
Ruijin Hospital
Phase EARLY_PHASE1
20
Shanghai
2024-07-16
Recruiting
The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer
NCT06368063Pancreatic Cancer Resectable
DrugHuaier
Xi'an Jiaotong University
Phase 4
642
Xi'an
2024-05-06
Active, closed
ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
NCT05479708Pancreatic Cancer Resectable
BAIYONG SHEN
Observational
150
Shanghai
2023-08-09
Rows per page Showing 1–11 of 11
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/pancreatic-cancer-resectable

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 11 of those studies listing the condition Pancreatic Cancer Resectable.

How many Pancreatic Cancer Resectable trials are recruiting in China?

4 of the 11 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 4 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Pancreatic Cancer Resectable), 11 studies
PhaseStudiesRecruitingShare
Observational6154.5%
Phase 22118.2%
Phase 1/2109.1%
Phase 4119.1%
Phase EARLY_PHASE1119.1%

Most active sponsors

Lead sponsors with the most studies (Pancreatic Cancer Resectable)
Lead sponsorStudiesRecruiting
Shanghai Zhongshan Hospital21
Zhejiang University20
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10
BAIYONG SHEN10
Ruijin Hospital11
Sun Yat-sen University10
Xi'an Jiaotong University11
Zhejiang Cancer Hospital10
Zhejiang Provincial People's Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.